ReShape Lifesciences Inc (NASDAQ:RSLS) has a beta value of 1.60 and has seen 140.88 million shares traded in the recent trading session. The company, currently valued at $3.65M, closed the recent trade at $1.11 per share which meant it gained $0.75 on the day or 206.52% during that session. The RSLS stock price is -2512.61% off its 52-week high price of $29.00 and 69.37% above the 52-week low of $0.34. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.55 million shares traded. The 3-month trading volume is 1.23 million shares.
The consensus among analysts is that ReShape Lifesciences Inc (RSLS) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.
ReShape Lifesciences Inc (NASDAQ:RSLS) trade information
Sporting 206.52% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the RSLS stock price touched $1.11 or saw a rise of 21.28%. Year-to-date, ReShape Lifesciences Inc shares have moved -75.22%, while the 5-day performance has seen it change 111.32%. Over the past 30 days, the shares of ReShape Lifesciences Inc (NASDAQ:RSLS) have changed 1.38%. Short interest in the company has seen 0.37 million shares shorted with days to cover at 0.11.
ReShape Lifesciences Inc (RSLS) estimates and forecasts
The company’s shares have lost -80.51% over the past 6 months. If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 76.96% over the past 5 years.
RSLS Dividends
ReShape Lifesciences Inc is expected to release its next earnings report on 2024-Nov-13 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
ReShape Lifesciences Inc (NASDAQ:RSLS)’s Major holders
Insiders own 14.01% of the company shares, while shares held by institutions stand at 16.64% with a share float percentage of 19.35%. Investors are also buoyed by the number of investors in a company, with ReShape Lifesciences Inc having a total of 13.0 institutions that hold shares in the company.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Concord Street Trust-Fidelity Extended Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund. As of Jan 31, 2025, the former fund manager holds about 0.07% shares in the company for having 2.39 shares of worth $2942.0 while later fund manager owns 860.0 shares of worth $1058.0 as of Dec 31, 2024, which makes it owner of about 0.03% of company’s outstanding stock.
